Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Bertipaglia, Lara (2008) Effetto dell'emodiafiltrazione con rigenerazione on-line dell'ultrafiltrato (HFR) sullo stress ossidativo nei pazienti con insufficienza renale terminale in dialisi cronica. [Tesi di dottorato]

Full text disponibile come:

Documento PDF

Abstract (inglese)

Cardiovascular disease remains the most common cause for the excess of morbidity and mortality in end-stage renal disease (ESRD) patients. Increased oxidative stress (OxSt), inflammation and endothelial dysfunction are recognized non-traditional cardiovascular risk factors in these patients. These patients, in fact, have increased levels of inflammation-related proteins, such as interleukin-6 (IL-6) and C-reactive protein (PCR), as well as OxSt-related proteins, such as NAD(P)H oxidase, which lead to reduced nitric oxide (NO) availability and endothelial dysfunction. The cause(s) of inflammation in dialysis have been shown to be multi-factorial and to include both factors arising from dialysis as well as other non-dialysis- related factors. Unfortunately, during the last 20 years the mortality rate in ESRD patients treated with dialysis has remained high, which has prompted the exploration of multiple strategies such as anti-inflammatory treatment using either pharmacological or dialysis-based approaches, to improve outcomes in these patients.
A novel dialysis technique, haemodiafiltration with online regeneration of ultrafiltrate (HFR), has recently been reported to reduce levels of inflammation-related proteins, such as tumour necrosis factor (TNF-?), IL-6 and PCR, counteracting the inflammatory state while no data are available on the effect of HFR on OxSt. HFR (double chamber HDF with reinfusion of ultrafiltrate regenerated through a charcoal-resin cartridge), combines the processes of diffusion, convection and adsorbance. During HFR, the ultrafiltrate derived from the convective section of the filter is processed in a charcoal-resin cartridge and the regenerated ultrafiltrate is reinfused into the bloodstream before the diffusive section of the filter. An additional feature is that the resin component of the cartridge adsorbs in particular pro-inflammatory cytokines. Given the important role played by OxSt and its associated molecules, including those related to inflammation in increasing cardiovascular disease (CVD) risk in end-stage renal disease (ESRD), HFR may be useful in reducing the levels of these molecules, and thereby, in reducing the morbidity and mortality of dialysis patients.
The aim of the current study was to evaluate the effect of dialysis using HFR on OxSt as assessed by plasma markers of OxSt such as oxidized low density lipoproteins (LDL), an indicator of cardiovascular risk factor, as well as gene and protein expression levels of OxSt-related proteins in mononuclear cells such as p22phox, a 22 kDa subunit of cytochrome b558 included in the NADH/NADPH oxidase which is present both in leucocytes and in the vascular wall which functions as an integral subunit of the final electron transport from NAD(P)H to haeme and molecular oxygen in generating O2, plasminogen activator inhibitor (PAI)-1, a proatherothrombogenic factor; haeme-oxygenase-1 (HO-1), one of three different isoforms of HO, it acts on haeme, producing CO and biliverdin, which is further metabolized to bilirubin, a potent antioxidant itself.
Eighteen patients from the Division of Nephrology II at the Padova University Hospital, age range 19-60 years, undergoing chronic dialysis treatment (210-240 min three times a week bicarbonate-dialysis) for at least 1 year (range 1-6 years), were recruited and randomized into a 1 year cross-over study. One group of patients was initially treated for 6 months with HFR (SG8 Plus-Bellco, Mirandola Italy) then followed by 6 months of low-flux bicarbonate dialysis with ultrapure dialysate, using a polysulphone dialyser 1.8m2 and the other group was first treated with low flux bicarbonate dialysis with ultrapure dialysate, using a polysulphone dialyser 1.8m2 for 6 months followed by 6 months of treatment using HFR.
Treatment with HFR significantly reduced mononuclear cell p22phox mRNA level and protein expression compared with the treatment with BD. Also mononuclear cell PAI-1 mRNA level and protein expression was significantly reduced by the treatment with HFR compared with the treatment with BD. Whereas treatment with HFR did not modify gene and protein expression of HO-1 compared with the treatment with BD. Treatment with HFR compared with the treatment with BD significantly reduced the plasma level of OxLDL: -14 ± 19 ?% vs 1 ± 14, p<0.01.
The results of this study indicate that the treatment with HFR has a much lower impact on OxSt, as the levels of expression of proteins related to and the level of markers of OxSt were lower than those seen with standard dialysis. The more plausible explanation may come from both the efficacy of HFR in reducing the level of pro-oxidant/proinflammatory cytokines such as TNF-?, IL-6, which are inducers of and involved in the OxSt and inflammatory response, and from a possible sparing effect of HFR on several water soluble antioxidants. These effects of HFR might contribute to reduce the oxidative status in dialysis patients in general and explain its effects compared with standard bicarbonate dialysis in reducing the gene and protein expression of the OxSt-related proteins. This lower impact on OxSt suggests that HFR is a more biocompatible system for dialysis. Given the very close relationships between OxSt and inflammation and the determinant role played by OxSt in the induction of inflammation-related mechanisms in ESRD patients, HFR treatment could have considerable clinical impact in reducing the risk of progressive atherosclerotic cardiovascular disease in dialysis patients, which is the main cause of death in these patients.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Froldi, Guglielmina
Correlatore:Calò, Lorenzo A.
Dottorato (corsi e scuole):Ciclo 20 > Corsi per il 20simo ciclo > FARMACOLOGIA E TOSSICOLOGIA, TERAPIA RIANIMATIVA E INTENSIVA
Data di deposito della tesi:31 Gennaio 2008
Anno di Pubblicazione:31 Gennaio 2008
Parole chiave (italiano / inglese):HFR, oxidative stress, pai-1, HO-1, p22phox
Settori scientifico-disciplinari MIUR:Area 05 - Scienze biologiche > BIO/14 Farmacologia
Struttura di riferimento:Dipartimenti > Dipartimento di Farmacologia ed Anestesiologia "E. Meneghetti"
Codice ID:317
Depositato il:22 Set 2008
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Abraham G, Bhaskaran S, Soundarajan P, Ravi R, Nitya S, Padma G, Jayanthi V. Continuous ambulatory peritoneal dialysis. J Assoc Physicians India. 1996 Sep;44(9):599-601. Cerca con Google

2. Ader JL, Rostaing L. Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Curr Opin Nephrol Hypertens. 1998 Sep;7(5):539-45. Cerca con Google

3. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005; 59:102-106. Cerca con Google

4. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 (suppl 92):S11-5. Cerca con Google

5. Applegate LA, Luscher P, Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res. 1991 Feb 1;51(3):974-8. Cerca con Google

6. Aruoma OI, Halliwell B, Dizdaroglou M. Iron ion-dependent modification of bases in DNA by the superoxide radical generating system hypoxanthine/xanthine oxidase. J Biol Chem 1989; 264:13024-13028. Cerca con Google

7. Aucella F, Gesuete A, Sereni L, Netti S, Savastano AM, Querques M, Specchio A, De Min A, Avanzi C, Montemurno C, Grandone E, Cappucci F, Procaccini DA, Stallone C, Gesualdo L; Gruppo collaborativo sull’HFR. [Acute biocompatibility of hemodiafiltration with endogenous reinfusion (HFR)]. G Ital Nefrol 2004 Nov-Dec; 21Suppl 30:S185-9. Cerca con Google

8. Aust SD, Morehouse LA, Thomas CE. Role of metals in oxygen radical reaction. Free Radic Biol Med 1985; 1:13-8. Cerca con Google

9. Babior BM. NADPH Oxidase. An Update. Blood 1999; 93(5):1464-1476. Cerca con Google

10. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99: 16093–16098. Cerca con Google

11. Birnboim HC, Kanabus-Kominska M. The production of DNA strand breaks in human Ieukocytes by superoxyde may involve a metabolic process. Proc Natl Acad Sci USA 1987; 82:6820-6824. Cerca con Google

12. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999 Sep;56(3):1078-83. Cerca con Google

13. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000 Oct 7;356(9237):1213-8. Cerca con Google

14. Calò L. Radicali liberi, superossidi, e stress ossidativo nella patogenesi e fisiopatologia dell’ipertensione arteriosa e delle sue complicanze. Current Therapeutics ADIS International 1999;1-8. Cerca con Google

15. Calò LA, Davis PA, Giacon B, Pagnin E, Sartori M, Riegler P, Antonello A, Huber W, Semplicini A. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002; 40:625-631. Cerca con Google

16. Calò LA, Davis PA, Piccoli A, Pessina AC. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story? Nephron Physiol 2006; 103: 107–111 Cerca con Google

17. Calò LA, Davis PA, Semplicini A, Pessina AC. L-carnitine and erythropoiesis: relationship with heme oxygenase-1. Nephrol Dial Transplant 2005; 20:1769-1770. Cerca con Google

18. Calò LA, Naso A, Pagnin E, Davis PA, Castoro M, Corradin R, Riegler P, Cascone C, Huber W, Piccoli A. Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis--a molecular biological approach. Clin Nephrol 2004; 62:355-61. Cerca con Google

19. Calò LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, Pessina C. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107: 54–60. Cerca con Google

20. Calò LA, Stanic L, Davis PA, , Pagnin E, Munaretto G, Fusaro M, Landini S, Semplicini A, Piccoli A. Effect of epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. Int J Clin Pharmacol Ther 2003; 41: 187–192 Cerca con Google

21. Ceriello A, Curcio F, dello Russo P, Pegoraro I, Stel G, Amstad P, Cerutti P. The defence against free radicals protects endothelial cells from hyperglycaemìainduced plasminogen activator inhibitor 1 over-production. Blood Coagul Fibrinolvsis 1995; 6:133-137. Cerca con Google

22. Chen YH, Yet SF, Perrella MA. Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood). 2003 May;228(5):447-53. Cerca con Google

23. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, and iron are required for TNF-[alfa]-induced MCP-1 gene expression in endothelial cells: role of Rac 1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 2004; 286:H1001-H1007. Cerca con Google

24. Choi AMK e Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-indcibile protein. Am J Respir Cell Biol 1996; 15:9-19. Cerca con Google

25. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1–derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol 2000;278:H643–H651. Cerca con Google

26. Cristofano C, Vernaglione L, Perniola MA, Lo Barco C, Muscogiuri P, Chimienti S. [Cystain C, beta2-microglobulin and C-reactive protein in hemodiafiltration and online endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis]. G Ital Nefrol 2004 Nov-Dec;21 Suppl 30:S197-200. Cerca con Google

27. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant. 1997 Nov;12(11):2312-7. Cerca con Google

28. De Angelis A, Tullio T, Ferrannini M, Vega A, Dessi MR, Casciani S, Ruggia R, Pastore A, Cortese C, Splendiani G. [Selective adsorption of homocysteine using HFR-on line technique]. G Ital Nefrol 2004 Nov-Dec;21 Suppl 30:S106-10. Cerca con Google

29. De Francisco ALM, Ghezzi PM, Brendolan A, et al. Hemodiafiltration with on-line regeneration of the ultrafiltrate. Kidney Int 2000;58(Suppl.76):66-71. Cerca con Google

30. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14:193-9. Cerca con Google

31. Dhalla NS, Temsha RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertension 2000; 18: 655-673. Cerca con Google

32. Dimova EY, Samoylenko A, Kietzmann T. Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxidants & Redox Signaling 2004; (6) 4:777-791. Cerca con Google

33. Du XL, Edeistein D, Rossetti L, Fantus IG, Goldberg 11, Ziyadeh E, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97:12222-12226. Cerca con Google

34. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med 2002; 7(3): 195-202. Cerca con Google

35. Eberhardt W, Beck KF, Pfeilschifter J. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidnev Int 2002; 61:20-30. Cerca con Google

36. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. Journal of Biological Chemistry 1990; 265:13029-13035. Cerca con Google

37. Emiliani G, Briganti M, Montanari A, Isola E, Fusaroli M. [On-line haemodiafiltration with sorbent-regenerated ultrafiltrate as replacement fluid: Beta2-microglobulin removal versus filtration fraction]. G Ital Nefrol 2004 Nov-Dec; 21 Suppl 30:S80-4. Cerca con Google

38. Esmon CT. Regulation of blood coagulation. Biochimica et Biophysica Acta 2000;1477:349-360. Cerca con Google

39. Fasianos E, Sacchetti A, Cataldi G et al: Hemodiafiltration with ondine reinfusion (on-line HFR) induces a minor loss of essential amino acids durino hemodialysis treatment. Nephrol Dial Transplant 2003; 18 (suppl 4):193. Cerca con Google

40. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis. 2006 Apr;185(2):219-26. Cerca con Google

41. Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant 2007; 22 Suppl 5: 20-36. Cerca con Google

42. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int. 1998 Aug;54(2):580-9. Cerca con Google

43. Galli F, Ronco C. Oxidant stress in hemodialysis. Nephron 2000; 84:1-5. Cerca con Google

44. Ghezzi PM, Bottella J, Sartoris AM, Gervasio R, Diez C. use of the ultrafiltrate obtained in two-chamber (PFD) hemodiafiltration as replacement fluid. Experimental ex vivo and in vitro study. Artif Kidney Dial 1991; 14:1458-64. Cerca con Google

45. Ghezzi PM, Gervasio R, Tessore V, Sartoris AM, Botella J: Hemodiafiltration without replacement fluid. An experimental study. ASAIO J 1992; 38:61–65. Cerca con Google

46. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. Journal of Clinical Investigation 1986; 78:1673-1680. Cerca con Google

47. Griendling KK, Minieri CA, Oilerenshaw ID. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148. Cerca con Google

48. Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86:494-501. Cerca con Google

49. Handelman GJ. Current studies on oxidant stress in dialysis. Blood Purif. 2003;21(1):46-50. Cerca con Google

50. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91:7A-11A. Cerca con Google

51. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997; 20(Suppl II):11-17. Cerca con Google

52. Hörl WH. Hemodialysis Membranes: Interleukins, Biocompatibility, and Middle Molecules. J Am Soc Nephrol 2002; 13:S62-S71. Cerca con Google

53. Immenschuh S, Ramadori G. Gene regulation of Heme Oxygenase-1 as a Therapeutic Target. Biochem Pharmacol 2000; 60:1121-1128. Cerca con Google

54. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB. Reactive oxygen species mediate TGF-beta1-induced plasmìnogen activator ìnhìbitor-1 upregulation in mesangial cells. Biochem Biophvs Res Commun 2003; 309:961- 966. Cerca con Google

55. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-462. Cerca con Google

56. Kaczorowski DJ, Zuckerbraun BS. Carbon monoxide: medicinal chemistry and biological effects. Curr Med Chem. 2007;14(25):2720-5. Cerca con Google

57. Kaide JI, Zhang F, Wei Y. Carbon monoxide of vascular origin attenuates the sensitivity of renal arterial vessels to vasoconstricotors. J Clin Invest 2001; 107: 1163-1171. Cerca con Google

58. Keyse SM, Tyrrel RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989; 86: 99-103. Cerca con Google

59. Kohler HP e Grant PJ. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801. Cerca con Google

60. La Dialisi – Centro studi Assobiomedica 2003. Cerca con Google

61. La Greca G, Brendolan A, Grezzi PM, et al. The concepì of sorbent in hemodialysis. Int J Artif Organs 1998; 21: 303-8. Cerca con Google

62. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: 1–47. Cerca con Google

63. Locatelli F, Canaud B, Eckardt K et al. Oxidative stress in endstage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272– 1280. Cerca con Google

64. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C and Zoccali C. Oxidative stress in endst-age renal disease: an emerging threat to patient outcome. Nephrol Dial Transpl 2003; 18:1272-80. Cerca con Google

65. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 (suppl 5): 69-80. Cerca con Google

66. Lonnemann G. Should ultra-pure dialysate be mandatory? Nephrol Dial Transplant. 2000;15 Suppl 1:55-9. Review. No abstract available. Cerca con Google

67. Luke RG. Chronic renal failure-a vasculopatic state. N Engl J Med 1998; 339: 841- 3. Cerca con Google

68. Lum H e Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280:C719-C741. Cerca con Google

69. Luskutoff DJ, Linders M, Kejier J, Veerman H, van Heerikhuizen H, Pannekoek H. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry 1987; 26:3763-3768. Cerca con Google

70. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517–554. Cerca con Google

71. Masuko UF, Maziar ZA, Toshiki F. p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin II – Induced Hypertrophy in Vascular Smotth Muscle Cells. J Biol Chem 1996; 271(38):23317-23321. Cerca con Google

72. Meisinger C, Baumert J, Khuseyinova N, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005; 112: 651- 657. Cerca con Google

73. Meloni C, Ghezzi PM, Cipriani S, Petroni S, Del Poeta G, Rossini B, Rossi V, Recino G, Suppo G, Cecilia A, Casciani CU. One year of clinical experience in postdilution hemofiltration with online reinfusion of regenerated ultrafiltrate. Blood Purif. 2004; 22(6):505-9. Cerca con Google

74. Memoli B. Cytokine production in haemodyalisis. Blood Purif 1999; 17:149-158. Cerca con Google

75. Mimuro J e Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction wìth extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264:936-939. Cerca con Google

76. Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Leger CL, Delcourt C, Papoz L, Descomps B, Canaud B. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant. 2002 Mar;17(3):422-7. Cerca con Google

77. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemod Int 2005; 9:37-46. Cerca con Google

78. Morita T, Kourembanas S. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J. Clin. Invest. 1995; 96:2676-2682. Cerca con Google

79. Morita T, Perrella MA, Lee M et al. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc. Natl. Acad. Sci. USA. 1995; 92:1475-1479. Cerca con Google

80. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappa 13 and free radical in proximai tubular cells. Kidney Int 2003; 63:1671-1680. Cerca con Google

81. Nath KA. Heme oxygenase-1: A provenance for cytoprotective pathways in the kidney and other tissues. Kidney International 2006; 70: 432-443. Cerca con Google

82. Nath KA, Vercellotti GM, Grande JP, et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int 2001; 59:106-117. Cerca con Google

83. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human betamigrating endothelial-cell-type plasminogen activator inhibitor. Proceeding of the National Academy of Sciences of the United States of America 1986; 83:6776-6780. Cerca con Google

84. Ohta K, Yachie A. Development of vascular biology over the past 10 years: heme oxygenase-1 in cardiovascular homeostasis. J Endovasc Ther 2004; 11 Suppl 2:II140-150. Cerca con Google

85. Ojo AO, Leichtman AB, Punch JD, Hanson JA, Dickinson DM, Wolfe RA, Port FK, Agodoa LY. Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric renal transplant outcomes. Am J Kidney Dis. 2000 Jul;36(1):153-9. Cerca con Google

86. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997 Apr 17;336(16):1131-41. Cerca con Google

87. Panichi V, Rizza GM, Taccola D, Paoletti S, Mantuano E, Migliori M, Frangioni S, Filippi C, Carpi A. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes. Biomed Pharmacother. 2006 Jan;60(1):14-7. Cerca con Google

88. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO Journal 1986; 5:2539-2544. Cerca con Google

89. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JL. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. Journal of Biological Chemistry 2000; 275:1 9788-1 9794. Cerca con Google

90. Ren S e Shen GX. lmpact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 1688-1693. Cerca con Google

91. Righetti M, Ferraio GM, Milani S, Serbelloni P, Sessa A. [A single centre study about the effects of HFR on anemia]. G Ital Nefrol 2004 Nov-Dec;21 Suppl 30:S168-71. Cerca con Google

92. Rosen GM, Pou J, Ramos CL. Free radicals and phagocytic cells. FASEB J 1995; 9:200-209. Cerca con Google

93. Ryter SW, Morse D, Choi AMK. Carbon monoxide and bilirubin potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol 2007; 36: 175–182. Cerca con Google

94. Schelotto C, Santoni O, Nasini MG, Pietrucci A, Caviglia PM, Tirotta A, Repetto M, Carozzi S. [Two-chamber hemodiafiltration: comparison between exogenous reinfusion (PFD) and endogenous reinfusion (HFR)]. G Ital Nefrol 2004 Nov-Dec;21 Suppl 30:S111-6. Cerca con Google

95. Sidoti A, Borracelli D, Biagioli M, Ghezzi PM. [Bicarbonate balance in hemodiafiltration (HDF): a comparison between two infusion methods of on-line prepared solution]. G Ital Nefrol 2004 Nov-Dec;21 Suppl 30:S177-80. Cerca con Google

96. Sirker A, Zhang M, Murdoch C, Shah AM. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol. 2007;27(6):649-60. Cerca con Google

97. Starkebaum G e Harlan JM. Endothelial-cell injury due to copper-catalyzed hydrogen-peroxide generation from homocysteine. J Clin Invest 1986; 77:1370- 1376. Cerca con Google

98. Stoker R, Yamamoto Y, McDonagh AF, et al. Bilirubin Is an Antioxidant of Possible Physiological Importance. Science. 1987; 235:1043-1046. Cerca con Google

99. Swiatkowska M, Szemraj J, Al Nedawi KN, Pawiowska Z. Reactive oxygen species upregulate ex pression of PAI-1 in endothelial cells. Cell Mol Biol Lett 2002; 7:1065- 1071. Cerca con Google

100. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 2007; 18: 414-420. Cerca con Google

101. Van Meijer M e Pannekoek H. structure of PAI-1 and its function in fibrinolysis: an update. Fibrynolisi 1995; 9:263-276. Cerca con Google

102. Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. Journal of Biological Chemistry 1984; 259:14914-14921. Cerca con Google

103. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3:1879-1883. Cerca con Google

104. Verma A, Hirsch DJ, Glatt CE, et al. Carbon monoxide: a putative neural messenger. Science. 1993; 259:381-384. Cerca con Google

105. Xu D, Neville R, Finkel T. Homocysteine accelerates endothelial cell senescence. FEBS Lett 2000; 470: 20-24. Cerca con Google

106. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibìtor-1 in human or animal disorders. Int J Hematol 1998; 68: 371- 385. Cerca con Google

107. Young, Woodside JW. Antioxidants in health and disease. J. Clin. Phatol. 2001;54(3):176-186. Cerca con Google

108. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994;74:139-162. Cerca con Google

109. Zhao W, Spitz DR, Oberley LW, Robbins ME. Redox modulation of the profìbrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res 2001; 61:5537-5543. Cerca con Google

110. Zoccali C. Cardiovascular risk in uremic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-7. Cerca con Google

111. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S77-80. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record